Caplin Point Laboratories, 524742, CAPLIPOINT Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

15,388.57
24.00
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

14,768.10
0.20%
4.29

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

23.29
12.79
9.72

EBITDA CAGR (%)

10 Years
5 Years
3 Years

25.99
14.81
7.99

PAT CAGR (%)

10 Years
5 Years
3 Years

27.90
17.23
12.54

P:E (Median)

8 Years
5 Years
3 Years

19.89
22.48
25.24

P:BV (Average)

8 Years
5 Years
3 Years

4.70
4.58
4.98

EV:EBITDA (Average)

8 Years
5 Years
3 Years

14.13
15.82
17.95

Earnings Forecasts:

(Updated: 23-05-2026)

Description 2024 2025 2026 2027
Adj EPS 83.05 93.79 106.93
P/E Ratio 24.36 21.57 18.92
Revenue 2137.9 2500.8 2805.3
EBITDA 748.2 860.4 981
Net Income 628.4 712.75 816.7
ROA 21.65 20.64 21.16
P/B Ratio 4.56 3.49 3.17
ROE 19.81 17.15 16.95
FCFF 437.72 558.57 531.06 3360.18
FCFF Yield 3.05 3.89 3.7 23.38
Net Debt 1391.6 1825.1 1695.6
BVPS 443.73 579.04 637.29

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 191.36 173.61 10.22% 189.22 185.23 2.15% 175.18 207.93 -15.75% 182.57 185.64 -1.65%
Expenses 107.77 98.57 9.33% 97.50 107.84 -9.59% 99.33 109.77 -9.51% 95.96 104.26 -7.96%
EBITDA 83.59 75.04 11.39% 91.72 77.39 18.52% 75.85 98.16 -22.73% 86.61 81.38 6.43%
EBIDTM 43.68% 43.22% 48.47% 41.78% 43.30% 47.21% 47.44% 43.84%
Other Income 61.08 41.25 48.07% 31.73 28.83 10.06% 59.22 43.01 37.69% 32.03 21.50 48.98%
Interest 0.05 0.04 25.00% 0.07 0.04 75.00% 0.05 0.02 150.00% 0.04 0.02 100.00%
Depreciation 6.90 6.09 13.30% 6.37 6.01 5.99% 6.02 6.49 -7.24% 6.14 6.18 -0.65%
PBT 137.72 110.16 25.02% 117.01 100.17 16.81% 129.00 134.66 -4.20% 112.46 96.68 16.32%
Tax 28.22 23.66 19.27% 29.73 25.46 16.77% 26.41 28.92 -8.68% 26.57 24.14 10.07%
PAT 109.50 86.50 26.59% 87.28 74.71 16.83% 102.59 105.74 -2.98% 85.89 72.54 18.40%
PATM 57.22% 49.82% 46.13% 40.33% 58.56% 50.85% 47.05% 39.08%
EPS 14.41 11.38 26.63% 11.48 9.83 16.79% 13.50 13.91 -2.95% 11.30 9.54 18.45%

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 600.16 502.45 19.45% 542.77 492.96 10.10% 534.04 483.10 10.54% 510.22 458.96 11.17%
Expenses 395.92 334.39 18.40% 353.08 330.67 6.78% 344.87 318.34 8.33% 332.46 307.15 8.24%
EBITDA 204.24 168.06 21.53% 189.69 162.29 16.88% 189.17 164.76 14.82% 177.76 151.81 17.09%
EBIDTM 34.03% 33.45% 34.95% 32.92% 35.42% 34.10% 34.84% 33.08%
Other Income 28.36 25.74 10.18% 33.68 31.36 7.40% 30.37 20.77 46.22% 23.14 18.56 24.68%
Interest 0.36 0.17 111.76% 0.18 0.18 0.00% 0.16 0.21 -23.81% 0.18 0.05 260.00%
Depreciation 18.80 17.04 10.33% 19.28 16.20 19.01% 18.40 16.76 9.79% 16.29 15.96 2.07%
PBT 213.44 176.59 20.87% 203.91 177.27 15.03% 200.98 168.56 19.23% 184.43 154.36 19.48%
Tax 40.56 31.39 29.21% 38.03 37.19 2.26% 40.77 37.65 8.29% 33.70 29.46 14.39%
PAT 172.88 145.20 19.06% 165.88 140.08 18.42% 160.21 130.91 22.38% 150.73 124.90 20.68%
PATM 28.81% 28.90% 30.56% 28.42% 30.00% 27.10% 29.54% 27.21%
EPS 22.38 18.76 19.30% 21.56 18.28 17.94% 20.32 17.21 18.07% 20.11 16.31 23.30%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 738.33 752.41 625.09 528.61 528.06 482.68 527.83 536.91 426.57 341.55 231.29 Net Sales Growth -1.87% 20.37% 18.25% 0.10% 9.40% -8.55% -1.69% 25.87% 24.89% 47.67% Cost Of Goods Sold 228.95 238.17 205.22 198.06 204.65 194.83 238.18 237.03 180.11 161.94 116.73 Gross Profit 509.38 514.24 419.87 330.55 323.41 287.85 289.65 299.87 246.46 179.61 114.56 GP Margin 68.99% 68.35% 67.17% 62.53% 61.24% 59.64% 54.88% 55.85% 57.78% 52.59% 49.53% Total Expenditure 400.56 420.44 338.01 309.23 308.58 273.14 320.83 348.31 284.60 247.72 168.78 Power & Fuel Cost - 14.11 15.43 9.89 9.54 6.36 7.19 12.29 10.96 9.85 7.55 % Of Sales - 1.88% 2.47% 1.87% 1.81% 1.32% 1.36% 2.29% 2.57% 2.88% 3.26% Employee Cost - 51.56 37.18 35.81 29.91 26.03 24.39 40.49 37.29 29.48 17.58 % Of Sales - 6.85% 5.95% 6.77% 5.66% 5.39% 4.62% 7.54% 8.74% 8.63% 7.60% Manufacturing Exp. - 63.82 54.17 42.18 34.68 27.15 33.34 38.72 37.02 28.34 13.84 % Of Sales - 8.48% 8.67% 7.98% 6.57% 5.62% 6.32% 7.21% 8.68% 8.30% 5.98% General & Admin Exp. - 22.48 18.24 13.52 12.55 7.25 11.70 17.00 14.11 12.59 7.60 % Of Sales - 2.99% 2.92% 2.56% 2.38% 1.50% 2.22% 3.17% 3.31% 3.69% 3.29% Selling & Distn. Exp. - 20.07 1.88 3.91 12.23 2.78 5.89 2.64 4.74 5.37 2.11 % Of Sales - 2.67% 0.30% 0.74% 2.32% 0.58% 1.12% 0.49% 1.11% 1.57% 0.91% Miscellaneous Exp. - 10.23 5.89 5.86 5.02 8.74 0.14 0.13 0.38 0.16 2.11 % Of Sales - 1.36% 0.94% 1.11% 0.95% 1.81% 0.03% 0.02% 0.09% 0.05% 1.46% EBITDA 337.77 331.97 287.08 219.38 219.48 209.54 207.00 188.60 141.97 93.83 62.51 EBITDA Margin 45.75% 44.12% 45.93% 41.50% 41.56% 43.41% 39.22% 35.13% 33.28% 27.47% 27.03% Other Income 184.06 134.59 105.84 99.54 56.69 23.01 65.97 35.40 23.59 12.51 3.47 Interest 0.21 0.12 0.10 0.12 0.09 0.17 0.19 0.50 0.52 0.50 0.31 Depreciation 25.43 24.77 27.08 25.65 25.77 22.44 19.65 20.84 18.99 13.26 7.30 PBT 496.19 441.67 365.74 293.15 250.31 209.94 253.12 202.65 146.05 92.58 58.38 Tax 110.93 102.18 82.03 58.89 62.44 53.71 55.49 54.49 43.74 22.26 13.05 Tax Rate 22.36% 23.13% 22.43% 20.09% 24.95% 25.58% 21.92% 26.89% 29.95% 24.04% 22.35% PAT 385.26 339.49 283.71 234.26 187.87 156.23 197.64 148.17 102.31 70.32 45.33 PAT before Minority Interest 385.26 339.49 283.71 234.26 187.87 156.23 197.64 148.17 102.31 70.32 45.33 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 52.18% 45.12% 45.39% 44.32% 35.58% 32.37% 37.44% 27.60% 23.98% 20.59% 19.60% PAT Growth 13.48% 19.66% 21.11% 24.69% 20.25% -20.95% 33.39% 44.82% 45.49% 55.13% EPS 50.69 44.67 37.33 30.82 24.72 20.56 26.01 19.50 13.46 9.25 5.96

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 2,187.19 1,937.47 1,694.10 1,466.73 1,269.41 1,061.29 863.20 648.69 539.84 401.65 238.72 Net Sales Growth 12.89% 14.37% 15.50% 15.54% 19.61% 22.95% 33.07% 20.16% 34.41% 68.25% Cost Of Goods Sold 865.68 770.84 724.18 663.21 557.51 471.74 413.16 288.78 238.18 184.93 121.16 Gross Profit 1,321.51 1,166.63 969.92 803.52 711.90 589.55 450.04 359.91 301.66 216.72 117.56 GP Margin 60.42% 60.21% 57.25% 54.78% 56.08% 55.55% 52.14% 55.48% 55.88% 53.96% 49.25% Total Expenditure 1,426.33 1,290.54 1,142.66 1,026.21 874.88 737.04 603.13 416.84 344.52 276.84 174.51 Power & Fuel Cost - 37.83 33.57 25.53 21.40 16.36 14.81 13.76 10.98 9.91 7.56 % Of Sales - 1.95% 1.98% 1.74% 1.69% 1.54% 1.72% 2.12% 2.03% 2.47% 3.17% Employee Cost - 177.15 142.66 136.12 114.74 101.97 67.15 45.58 37.61 29.71 17.92 % Of Sales - 9.14% 8.42% 9.28% 9.04% 9.61% 7.78% 7.03% 6.97% 7.40% 7.51% Manufacturing Exp. - 120.13 117.73 90.99 82.01 69.85 68.23 43.49 37.11 28.56 14.33 % Of Sales - 6.20% 6.95% 6.20% 6.46% 6.58% 7.90% 6.70% 6.87% 7.11% 6.00% General & Admin Exp. - 112.05 92.97 85.38 66.68 49.52 29.69 23.02 14.62 13.73 8.15 % Of Sales - 5.78% 5.49% 5.82% 5.25% 4.67% 3.44% 3.55% 2.71% 3.42% 3.41% Selling & Distn. Exp. - 62.25 24.88 18.78 27.52 18.03 9.95 2.08 5.92 9.41 2.29 % Of Sales - 3.21% 1.47% 1.28% 2.17% 1.70% 1.15% 0.32% 1.10% 2.34% 0.96% Miscellaneous Exp. - 10.29 6.67 6.20 5.02 9.57 0.14 0.13 0.10 0.59 2.29 % Of Sales - 0.53% 0.39% 0.42% 0.40% 0.90% 0.02% 0.02% 0.02% 0.15% 1.30% EBITDA 760.86 646.93 551.44 440.52 394.53 324.25 260.07 231.85 195.32 124.81 64.21 EBITDA Margin 34.79% 33.39% 32.55% 30.03% 31.08% 30.55% 30.13% 35.74% 36.18% 31.07% 26.90% Other Income 115.55 96.43 66.94 56.52 38.89 27.93 41.33 19.03 12.67 9.96 3.66 Interest 0.88 0.61 0.78 0.78 0.70 1.59 0.32 0.58 0.61 0.52 0.34 Depreciation 72.77 65.96 53.44 44.99 46.90 36.97 31.62 23.43 19.00 13.30 7.48 PBT 802.76 676.79 564.16 451.27 385.82 313.62 269.46 226.88 188.38 120.95 60.05 Tax 153.06 135.69 103.01 74.36 77.37 62.19 54.38 50.32 43.74 25.44 14.28 Tax Rate 19.07% 20.05% 18.26% 16.48% 20.05% 19.83% 20.18% 22.18% 23.22% 21.03% 23.78% PAT 649.70 536.31 457.09 376.26 299.84 242.27 215.00 176.56 144.78 95.61 45.77 PAT before Minority Interest 641.21 541.09 461.42 376.99 308.45 251.43 215.08 176.56 144.63 95.50 45.77 Minority Interest -8.49 -4.78 -4.33 -0.73 -8.61 -9.16 -0.08 0.00 0.15 0.11 0.00 PAT Margin 29.70% 27.68% 26.98% 25.65% 23.62% 22.83% 24.91% 27.22% 26.82% 23.80% 19.17% PAT Growth 20.07% 17.33% 21.48% 25.49% 23.76% 12.68% 21.77% 21.95% 51.43% 108.89% EPS 85.49 70.57 60.14 49.51 39.45 31.88 28.29 23.23 19.05 12.58 6.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 1,700.93 1,390.15 1,139.91 930.65 758.67 599.91 432.04 295.60 200.12 128.14 Share Capital 15.20 15.19 15.18 15.16 15.13 15.13 15.13 15.12 15.12 15.11 Total Reserves 1,666.09 1,360.74 1,109.36 900.04 728.75 575.34 410.06 277.19 184.91 111.40 Non-Current Liabilities 13.70 13.29 16.42 24.63 24.99 27.16 24.77 27.86 19.90 13.69 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.02 0.29 0.32 0.48 0.73 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 0.85 0.43 0.00 0.00 0.00 0.00 0.00 0.00 0.40 1.63 Current Liabilities 99.85 118.87 146.85 98.88 77.33 64.26 82.51 87.34 97.05 120.77 Trade Payables 60.96 78.62 70.63 65.02 70.11 51.41 59.50 72.89 66.01 51.47 Other Current Liabilities 28.21 36.26 65.26 32.66 6.06 11.97 21.76 13.86 29.37 60.37 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 10.68 3.99 10.96 1.20 1.16 0.87 1.25 0.58 1.67 8.92 Total Liabilities 1,814.48 1,522.31 1,303.18 1,054.16 860.99 691.33 539.32 410.80 317.07 262.60 Net Block 205.26 165.79 156.85 162.46 182.68 166.93 137.77 169.32 151.75 142.75 Gross Block 381.41 318.45 285.13 268.64 266.22 228.35 179.85 231.63 195.07 178.70 Accumulated Depreciation 176.15 152.66 128.28 106.18 83.54 61.43 42.08 62.31 43.32 35.94 Non Current Assets 988.79 819.21 641.48 448.49 348.35 310.59 251.37 197.59 180.34 147.78 Capital Work in Progress 20.64 27.75 42.68 2.60 1.36 3.77 8.62 15.29 3.42 0.23 Non Current Investment 491.11 346.17 274.97 212.73 138.64 135.54 98.62 1.87 14.58 1.43 Long Term Loans & Adv. 257.13 272.07 164.70 70.70 5.67 4.36 6.36 11.11 10.59 3.37 Other Non Current Assets 14.65 7.43 2.28 0.00 20.00 0.00 0.00 0.00 0.00 0.00 Current Assets 825.69 703.10 661.70 605.67 512.64 380.74 287.95 213.21 136.73 114.82 Current Investments 311.33 237.98 210.18 51.97 10.54 60.23 69.62 46.34 4.20 0.00 Inventories 66.26 86.25 51.53 42.81 24.87 22.37 23.52 28.46 22.29 17.90 Sundry Debtors 175.33 128.67 88.24 53.73 98.46 218.98 125.39 86.35 3.21 6.80 Cash & Bank 214.71 215.78 271.38 316.08 345.49 58.27 44.85 28.28 76.66 64.77 Other Current Assets 58.06 14.68 2.17 11.97 33.28 20.89 24.56 23.78 30.37 25.35 Short Term Loans & Adv. 27.36 19.74 38.20 129.11 14.97 10.57 15.95 17.00 23.05 14.93 Net Current Assets 725.84 584.23 514.85 506.79 435.31 316.48 205.44 125.87 39.67 -5.95 Total Assets 1,814.48 1,522.31 1,303.18 1,054.16 860.99 691.33 539.32 410.80 317.07 262.60

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 2,850.49 2,315.71 1,880.48 1,483.93 1,185.83 947.91 632.91 363.83 224.76 128.14 Share Capital 89.78 89.77 89.76 89.74 89.71 89.71 51.05 15.12 15.12 15.11 Total Reserves 2,741.06 2,211.72 1,775.35 1,378.74 1,081.33 848.76 575.01 345.42 209.56 111.40 Non-Current Liabilities 13.24 7.89 2.13 12.55 17.39 24.86 23.42 27.86 19.90 13.69 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.02 0.29 0.32 0.48 0.73 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 1.74 9.04 7.78 8.48 5.69 5.23 0.13 0.00 0.40 1.63 Current Liabilities 305.99 330.85 268.00 207.68 142.85 144.32 86.11 108.67 113.36 125.04 Trade Payables 217.58 229.62 152.56 155.94 88.50 64.14 60.47 94.23 78.60 55.71 Other Current Liabilities 64.28 90.29 99.94 48.68 51.87 79.28 24.20 13.86 33.09 60.39 Short Term Borrowings 0.55 0.28 3.41 0.50 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 23.58 10.66 12.09 2.56 2.48 0.91 1.44 0.58 1.67 8.94 Total Liabilities 3,205.62 2,685.57 2,177.40 1,730.11 1,363.61 1,125.75 742.52 500.45 358.38 267.14 Net Block 545.78 452.66 279.81 286.57 305.34 272.50 226.84 169.48 151.83 144.23 Gross Block 859.52 702.31 480.32 445.74 422.58 354.79 271.51 231.79 195.15 180.76 Accumulated Depreciation 313.74 249.65 200.51 159.17 117.24 82.29 44.67 62.31 43.31 36.53 Non Current Assets 1,071.67 792.65 625.21 432.29 349.04 303.23 248.83 196.34 179.16 148.61 Capital Work in Progress 143.50 116.62 220.71 17.73 13.88 20.12 9.70 15.29 3.42 0.23 Non Current Investment 279.13 137.63 70.52 37.01 0.66 0.56 0.33 0.33 13.24 0.44 Long Term Loans & Adv. 88.61 78.31 51.51 89.90 7.92 10.05 11.95 11.23 10.67 3.71 Other Non Current Assets 14.65 7.43 2.66 1.08 21.24 0.00 0.00 0.00 0.00 0.00 Current Assets 2,133.95 1,892.92 1,552.19 1,297.82 1,014.57 822.53 493.69 304.11 179.22 118.53 Current Investments 311.33 237.98 210.18 51.97 10.54 60.23 69.62 46.34 4.20 0.00 Inventories 336.10 363.04 288.22 227.31 179.01 238.23 37.45 28.46 22.29 18.81 Sundry Debtors 632.49 542.72 394.06 317.05 279.36 228.96 159.81 125.88 33.02 7.95 Cash & Bank 591.41 552.74 493.48 462.99 438.33 223.43 152.99 79.28 93.07 68.10 Other Current Assets 262.62 50.43 22.82 13.61 107.33 71.68 73.83 24.16 26.63 23.67 Short Term Loans & Adv. 185.51 146.01 143.43 224.89 87.08 56.81 64.61 17.28 19.31 12.58 Net Current Assets 1,827.96 1,562.07 1,284.19 1,090.14 871.72 678.21 407.58 195.44 65.86 -6.51 Total Assets 3,205.62 2,685.57 2,177.40 1,730.11 1,363.61 1,125.76 742.52 500.45 358.38 267.14

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 195.87 111.01 157.10 230.97 294.64 87.01 107.34 22.61 55.49 44.37 PBT 441.67 365.74 293.15 250.31 209.94 253.12 202.65 146.05 92.58 58.38 Adjustment -84.47 -68.57 -59.57 -19.43 7.75 -32.58 -0.29 3.44 8.06 3.89 Changes in Working Capital -57.49 -99.07 -11.45 62.07 131.85 -83.19 -54.17 -92.59 -24.76 -7.20 Cash after chg. in Working capital 299.71 198.10 222.13 292.95 349.54 137.36 148.19 56.90 75.88 55.07 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -103.84 -87.09 -65.03 -61.98 -54.90 -50.35 -40.84 -34.29 -20.39 -10.69 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -140.20 -118.94 -86.67 -275.93 -3.71 -41.06 -76.51 -59.71 -37.07 -5.98 Net Fixed Assets -55.85 -18.39 -56.57 -3.66 -35.46 -43.65 58.45 -48.43 -19.56 -7.66 Net Investments -218.29 -99.00 -220.45 -115.52 46.59 -27.53 -120.03 -29.43 -17.35 0.01 Others 133.94 -1.55 190.35 -156.75 -14.84 30.12 -14.93 18.15 -0.16 1.67 Cash from Financing Activity -38.10 -34.26 -30.42 -22.76 -3.47 -32.92 -15.21 -11.60 -6.74 -13.95 Net Cash Inflow / Outflow 17.57 -42.19 40.01 -67.72 287.46 13.03 15.62 -48.70 11.67 24.45 Opening Cash & Equivalents 80.64 122.02 81.01 148.82 55.61 42.52 26.18 74.89 63.22 40.32 Closing Cash & Equivalent 99.64 80.64 122.02 81.01 342.88 55.61 42.52 26.18 74.89 64.77

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 432.37 318.39 271.37 336.73 268.61 44.68 83.42 66.49 67.61 42.40 PBT 676.78 564.43 451.35 385.82 313.62 269.46 226.88 188.38 120.95 60.05 Adjustment 5.51 2.40 11.77 30.44 23.09 7.09 19.12 14.84 8.61 3.87 Changes in Working Capital -122.28 -139.44 -103.75 1.96 -1.96 -177.11 -120.06 -100.38 -38.39 -5.13 Cash after chg. in Working capital 560.01 427.39 359.37 418.22 334.75 99.44 125.94 102.84 91.16 58.78 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -127.64 -109.00 -88.00 -81.49 -66.14 -54.76 -42.51 -36.35 -23.55 -16.38 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -334.73 -320.04 -217.58 -376.77 -29.44 -54.50 -100.46 -69.02 -36.11 -5.72 Net Fixed Assets -55.85 -18.39 -56.57 -3.66 -35.46 -43.65 58.45 -48.43 -19.56 -7.66 Net Investments -218.29 -99.00 -220.45 -115.52 46.59 -27.53 -120.03 -29.43 -17.35 0.01 Others -60.59 -202.65 59.44 -257.59 -40.57 16.68 -38.88 8.84 0.80 1.93 Cash from Financing Activity -38.32 -38.07 -28.17 -40.68 -23.98 79.77 89.79 -11.60 -6.74 -13.95 Net Cash Inflow / Outflow 59.32 -39.72 25.62 -80.72 215.19 69.94 72.76 -14.13 24.76 22.73 Opening Cash & Equivalents 138.70 177.56 150.76 231.57 220.77 150.65 77.17 91.31 66.55 45.37 Closing Cash & Equivalent 193.74 134.20 170.92 150.76 435.72 220.77 150.65 77.17 91.31 68.10

Financial Ratios

Consolidated /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 221.22 181.16 148.16 120.74 98.33 78.06 56.22 38.66 26.47 16.25 ROA 20.35% 20.08% 19.87% 19.62% 20.13% 32.12% 31.19% 28.11% 24.26% 18.66% ROE 22.21% 22.69% 22.97% 22.65% 23.42% 38.92% 41.30% 41.56% 43.57% 42.62% ROCE 28.58% 28.92% 28.33% 29.64% 30.92% 49.05% 55.76% 58.99% 56.89% 53.75% Fixed Asset Turnover 2.15 2.07 1.91 1.97 1.95 2.59 2.61 2.00 1.83 1.45 Receivable days 73.74 63.33 49.01 52.60 120.02 119.07 71.97 38.32 5.35 5.38 Inventory Days 36.99 40.23 32.57 23.39 17.86 15.87 17.67 21.71 21.48 24.11 Payable days 106.95 132.73 124.99 120.50 113.83 61.02 67.67 86.81 85.61 98.57 Cash Conversion Cycle 3.77 -29.17 -43.41 -44.52 24.05 73.91 21.97 -26.78 -58.79 -69.08 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 Interest Cover 3681.58 3658.40 2443.92 2782.22 1235.94 1369.24 404.61 281.22 185.02 190.79

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 362.67 293.21 235.91 183.89 144.94 114.21 78.03 47.69 29.73 16.25 ROA 18.37% 18.98% 19.30% 19.94% 20.20% 23.02% 28.41% 33.68% 30.54% 18.46% ROE 21.72% 22.97% 23.68% 24.77% 25.65% 29.58% 37.14% 49.43% 54.97% 43.13% ROCE 26.22% 26.92% 26.85% 28.77% 28.82% 33.35% 45.59% 64.08% 69.03% 55.41% Fixed Asset Turnover 2.48 2.87 3.17 2.92 2.73 2.76 2.58 2.53 2.14 1.48 Receivable days 110.70 100.92 88.48 85.74 87.41 82.19 80.37 53.72 18.62 10.40 Inventory Days 65.86 70.16 64.15 58.42 71.75 58.28 18.54 17.16 18.68 24.83 Payable days 105.88 96.31 84.89 80.02 59.05 28.33 65.76 89.68 88.17 103.48 Cash Conversion Cycle 70.68 74.76 67.73 64.14 100.11 112.15 33.15 -18.80 -50.88 -68.24 Total Debt/Equity 0.00 0.00 0.00 0.00 0.01 0.04 0.00 0.00 0.00 0.02 Interest Cover 1110.48 724.63 579.65 552.17 198.25 843.86 391.22 309.72 235.08 179.35

Top Investors:

investor education and protection fund authority ministry of corporate affairs

uti multi cap fund

pinebridge global funds - pinebridge india equity fund

Annual Reports:

News Update:

Caplin Point Laboratories’ arm gets USFDA approval for Foscarnet Sodium injection
15th May 2026, 10:08 AM

Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag) had US sales of around $15 million for the 12-month period ending March 2026
Read More
Caplin Point Lab - Quarterly Results
15th May 2026, 00:00 AM

Read More
Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection
5th May 2026, 15:12 PM

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia
Read More
Caplin Point’s arm gets USFDA’s final nod for Potassium Phosphates Injection
13th Mar 2026, 14:27 PM

According to IQVIATM, Potassium Phosphates injection USP had US sales of around $57 million for the 12-month period ending January 2026
Read More
Caplin Point’s arm secures USFDA’s final approval for Desmopressin Acetate Injection
2nd Mar 2026, 10:07 AM

Desmopressin Acetate Injection is used to treat conditions like haemophilia A, von Willebrand disease, and central diabetes insipidus
Read More
Caplin Point Laboratories’ arm gets USFDA’s approval for Sodium Phosphates Injection
24th Feb 2026, 12:58 PM

Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids
Read More

Caplin Point Laboratories Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524742 | NSE: CAPLIPOINT

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Caplin Point Laboratories Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524742 | NSE: CAPLIPOINT

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: